SYTL2 (synaptotagmin-like 2) functions as a vesicle trafficking regulator with distinct roles depending on isoform and cellular context. The protein acts as a RAB27A effector that facilitates cytotoxic granule exocytosis in lymphocytes and promotes angiogenic factor trafficking in cancer cells 12. SYTL2 binds phosphatidylserine and phosphatidylinositol-4,5-bisphosphate to regulate vesicle docking and membrane recruitment processes. In cancer biology, SYTL2 demonstrates significant pathological relevance across multiple malignancies. It promotes metastatic potential in ovarian cancer through enhanced cell migration and invasiveness, with expression regulated by DNA methylation mechanisms 3. In prostate cancer, SYTL2 enhances metastasis by stabilizing FSCN1 protein and promoting pseudopodia formation 4. The protein also contributes to angiogenesis in alveolar soft part sarcoma, where ASPSCR1::TFE3 fusion protein upregulates SYTL2 along with RAB27A to facilitate trafficking of angiogenic factors like PDGFB and VWF 12. Additionally, SYTL2 serves as a diagnostic marker for thoracic aortic aneurysm, correlating with inflammatory cell infiltration 5, and shows associations with hippocampal volume changes in depression 6. These findings establish SYTL2 as a critical regulator of vesicle trafficking with significant implications in cancer metastasis and cardiovascular disease.